Project Grant R34AR084669
Award Date
9/17/24
Completion Date
8/31/27
Dollars Obligated
$317K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Galveston, TX 77555, USA
Similar Awards
This Project Grant award for $593,598 was provided by the National Institutes of Health (NIH) Office of the Director under the Research Infrastructure Programs (CFDA 93.351). The award will fund the acquisition of a Waters Desorption Electrospray (DESI) XEVO TQ Absolute Imaging Mass Spectrometry System for the Sealy Institute for Drug Discovery (SIDD) at the University of Texas Medical Branch (UTMB). This specialized mass spectrometry instrument will enable advanced mass spectrometry imaging...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training Program provides $440,000.00 to the University of Texas Medical Branch at Galveston (UTMB) over a period from May 15, 2025 to February 28, 2030. The award supports two research subprojects: The first subproject aims to build a quantitative understanding of how contractile injection systems, such as phage tails and tailocins, breach bacterial...
This $429,114 federal Project Grant award from the National Science Foundation's Engineering program (CFDA 47.041) will fund the development and validation of a first-of-its-kind multi-tissue on-a-chip breast-skin platform. The platform will feature integrated blood and lymphatic vasculature to study the spatial and temporal processes of lymphovascular space invasion (LVSI), dermal lymphatic invasion (DLI), and skin metastasis in breast cancer. The central hypothesis is that the cross-talk...
This Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research into the mechanism of skin blistering caused by chemical warfare agents. The $260,000 award, effective from December 16, 2024 through November 30, 2027, will enable the University of Chicago to investigate the role of the cytoskeleton and cell adhesion dynamics in...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under CFDA Program 93.310 - Trans-NIH Research Support, provides $1,476,000.00 to The University of Texas Southwestern Medical Center to develop and apply innovative tools to study the role of subcellular redox circuits in tumor metastasis. The project aims to address key questions about how highly metastatic tumors overcome oxidative stress, using advanced in vivo optogenetic approaches,...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of large-scale composite hypothesis testing approaches to perform translational genetics analyses. The $408,750 award, made effective September 15, 2024, will be used by the University of Texas MD Anderson Cancer Center to create novel, interpretable, and robust statistical strategies for conducting pleiotropy,...
The National Institute of General Medical Sciences (NIGMS) awarded a $1,149,182 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to the University of Texas at Austin (UT Austin). The grant, effective July 1, 2024 through May 31, 2029, supports research to elucidate the formation and repair mechanisms of DNA-protein cross-links (DPCs) and investigate the functions and regulatory mechanisms of the DNA repair enzyme TREX1. The research aims to advance...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $713,277 to Boston University Medical Campus to conduct research on the translational impact of genetic susceptibility to complex toxic exposures on blood-brain barrier function and age-related neurological outcomes in Gulf War Illness. The award will support the project from September 1, 2024 through August 31, 2027. As part of this...
This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $909,532.00 to The University of Texas Southwestern Medical Center to conduct research on validating a nonopioid analgesic pathway in human sensory ganglia and spinal cord. The award has a performance period from September 15, 2024 to September 14, 2025. The research aims to explore innovative, non-opioid based approaches to pain management, which is a...
This federal Project Grant award, totaling $999,465.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports research at the University of Houston System to develop selective spleen-targeted nanoparticles as drug delivery vehicles for the treatment of lupus. The project aims to advance innovative therapeutic approaches for this autoimmune disorder, with a focus on transforming healthcare for military service...